Table 1 Patient demographics and clinical characteristics
| Â | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | Summary (median or %) |
|---|---|---|---|---|---|---|---|---|---|
Age (years) | 3.4 | 9.7 | 10.4 | 16.8 | 17.2 | 17.4 | 17.5 | 18.5 | 17.0 |
Gender | F | M | M | M | F | M | M | M | M 75% |
Race | W | W | AA | AA | AA | AA | AA | AA | AA 75% |
Cause of ESKD | Aplasia | MCD | Obstructive uropathy | FSGS | FSGS | FSGS | Dysplasia | Obstructive uropathy | Â |
Duration on HD (months) | 21.9 | 4.1 | 75.2 | 5.8 | 2.3 | 1.4 | 2.7 | 2.3 | 3.4 |
Vascular access | Catheter | Catheter | Catheter | Catheter | Catheter | Fistula | Catheter | Fistula | Catheter 75% |
Dialysis settings (avg per session) | |||||||||
 Duration (hr) | 3.9 | 4.2 | 4.2 | 3.7 | 4.2 | 3.6 | 3.3 | 4.1 | 4 |
 Prescribed Qb (ml/min) | 86 | 200 | 150 | 350 | 350 | 350 | 400 | 440 | 350 |
 UF volume (L) | 0.2 | 1.0 | 1.2 | 3.8 | 2.7 | 2.1 | 2.4 | 3.2 | 2.25 |
Number of paired pre/post visits | 2 | 5 | 2 | 5 | 1 | 5 | 5 | 4 | 4.5 |
Number of anti-HTN medications | 0 | 2 | 2 | 0 | 2 | 3 | 0 | 3 | 2.5 |
HTN medication class | - | CCB α1-blocker | CCB α1-blocker | - | CCB α1-blocker | ARB α1-blocker Β-blocker | - | CCB α1-blocker ACEI | anti-HTN medication 62.5% |
Growth hormone | Yes | No | Yes | No | No | No | No | No | Yes 25% |
Completed isotope visit | Yes | Yes | No | Yes | No | Yes | Yes | Yes | Yes 75% |